SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Morepen Laboratories - Quaterly Results

29 Jul 2022 Evaluate
The sales slipped to Rs. 2743.97 millions for the June 2022 quarter as against Rs. 3652.31 millions during the year-ago period.Net profit was down at Rs. 68.75  millions against Rs. 308.47 millions recorded in the corresponding quarter a year ago.The net profit spiraled down by -77.71%.Operating profit for the quarter ended June 2022 decreased to 143.18 millions as compared to 442.26 millions of corresponding quarter ended June 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 2743.97 3652.31 -24.87 2743.97 3652.31 -24.87 14492.67 11124.23 30.28
Other Income 7.09 15.83 -55.21 7.09 15.83 -55.21 102.35 117.74 -13.07
PBIDT 143.18 442.26 -67.63 143.18 442.26 -67.63 1393.72 1241.47 12.26
Interest 3.95 2.11 87.20 3.95 2.11 87.20 -73.66 17.88 -511.97
PBDT 139.23 440.15 -68.37 139.23 440.15 -68.37 1467.38 1223.59 19.92
Depreciation 43.71 53.96 -19.00 43.71 53.96 -19.00 211.95 281.10 -24.60
PBT 95.52 386.19 -75.27 95.52 386.19 -75.27 1255.43 942.49 33.20
TAX 26.77 77.72 -65.56 26.77 77.72 -65.56 244.81 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 24.83 0.00 0.00
PAT 68.75 308.47 -77.71 68.75 308.47 -77.71 1010.62 942.49 7.23
Equity 998.27 899.59 10.97 998.27 899.59 10.97 955.59 899.59 6.23
PBIDTM(%) 5.22 12.11 -56.91 5.22 12.11 -56.91 9.62 11.16 -13.83

Morepen Laboratories Share Price

41.92 0.79 (1.92%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×